582 16 Linköping
BioReperia is a privately-owned start-up that was founded in September 2015 based on technology developed at Linköping University in Sweden. We have a Swiss subsidiary since 2019. Our QMS system (ISO13485 according to IVDR regulations) will be finalized in Q1 2021. Our ZTX™ technology is used in clinical trials to predict the efficacy of individual anti-cancer treatments on specific patients and to accelerate drug discovery for pharmaceutical companies.
We are active as CRO at the European and US market for drug discovery in both Academia and Pharma.
The company vision BioReperia´s vision is to radically reduce cancer mortality by predicting the most efficient cancer treatments for each individual patient within a week.